Table 1.
Adjusted analysis for factors associated with disease-related, treatment-related, and overall morbidity experienced during adolescence.
| Disease-related morbiditya | Treatment-related morbidityb | Overall morbidityc | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Event/person-years | IRR [95%CI] | p | Events/person-years | IRR [95%CI] | p | Events/person-years | IRR [95%CI] | p |
| Age (years) | |||||||||
| 10–14 | 1469/12,211 | 1.0 | 580/12,186 | NS | 2,046/12,235 | 1.0 | |||
| 15–19 | 170/5,558 | 0.2 [0.2, 0.3] | <0.001 | 343/5,566 | NS | 513/5,543 | 0.7 [0.6, 0.8] | <0.001 | |
| Sex | |||||||||
| Male | 781/8,378 | NS | 432/8,375 | NS | 1,213/8,382 | NS | |||
| Female | 858/9,392 | NS | 491/9,377 | NS | 1,349/9,396 | NS | |||
| CD4 count (cells/μL) | |||||||||
| ≥500 | 393/11,835 | 1.0 | 590/11,865 | 1.0 | 983/11,838 | 1.0 | |||
| 350–499 | 149/2,404 | 1.3 [1.0, 1.7] | 0.04 | 101/2,424 | 0.8 [0.6, 1.0] | 0.05 | 250/2,390 | 1.0 [0.8, 1.2] | 0.9 |
| 200–349 | 187/1,382 | 2.3 [1.7, 3.0] | <0.001 | 87/1,424 | 1.5 [1.1, 2.0] | 0.02 | 274/1,377 | 1.9 [1.5, 2.4] | <0.001 |
| <200 | 638/1,745 | 5.3 [4.1, 6.8] | <0.001 | 128/1,912 | 1.8 [1.3, 2.4] | <0.001 | 766/1,738 | 2.6 [2.1, 3.4] | <0.001 |
| HIV viral load (copies/mL) | |||||||||
| <400 | 242/11,368 | 1.0 | 619/11,447 | 1.0 | 861/11,363 | 1.0 | |||
| 400–999 | 16/370 | 1.4 [0.8, 2.3] | 0.3 | 22/379 | 0.7 [0.4, 1.2] | 0.2 | 38/369 | 0.9 [0.6, 1.4] | 0.6 |
| 1,000–4,999 | 49/560 | 2.9 [2.0, 4.0] | <0.001 | 21/568 | 0.6 [0.4, 1.1] | 0.08 | 70/560 | 1.2 [0.8, 1.6] | 0.3 |
| 5,000–9,999 | 17/268 | 2.1 [1.2, 3.5] | 0.006 | 23/273 | 1.1 [0.7, 1.9] | 0.7 | 40/269 | 1.3 [0.9, 2.0] | 0.2 |
| ≥10,000 | 390/1,846 | 4.8 [3.8, 6.0] | <0.001 | 107/1,921 | 0.9 [0.7, 1.3] | 0.7 | 497/1,831 | 1.9 [1.5, 2.3] | <0.001 |
| Age at ART initiation (years) | |||||||||
| <5 | 254/4,518 | 1.1 [0.8, 1.4] | 0.5 | 310/4,503 | 1.8 [1.5, 2.3] | <0.001 | 564/4,520 | 1.6 [1.3, 2.0] | <0.001 |
| 5–9 | 448/8,091 | 1.0 | 343/8,090 | 1.0 | 791/8,094 | 1.0 | |||
| ≥10 | 932/5,144 | 1.0 [0.8, 1.2] | 0.9 | 270/5,144 | 1.7 [1.2, 2.4] | 0.006 | 1,202/5,148 | 1.5 [1.1, 2.0] | 0.02 |
| Naive | 5/17 | - | - | - | - | - | 5/17 | - | - |
| Disease-related morbidity <10 years of age | |||||||||
| No | 143/2,699 | NS | 90/2,699 | 1.0 | NA | NA | |||
| Yes | 638/10,343 | NS | 582/10,335 | 1.5 [1.1, 2.1] | 0.005 | NA | NA | ||
| Treatment-related morbidity <10 years of aged | |||||||||
| No | 700/11,741 | NS | 527/11,733 | 1.0 | NA | NA | |||
| Yes | 81/1,301 | NS | 145/1,301 | 2.0 [1.5, 2.6] | <0.001 | NA | NA | ||
| Any morbidity <10 years of age | |||||||||
| No | NA | NA | NA | NA | 228/2,592 | 1.0 | |||
| Yes | NA | NA | NA | NA | 1,225/10,456 | 1.9 [1.4, 2.5] | <0.001 | ||
Adjusted analysis results only reported for characteristics that had a p-value <0.1 on univariate analysis. Bold signifies statistically significant variable.
Any reported symptomatic HIV-related clinical event meeting WHO clinical staging criteria.15
Any reported suspected or confirmed antiretroviral-associated adverse event meeting the US National Institutes of Health Division of AIDS criteria for adverse events.16
Incorporates both disease- and treatment-related morbidity. ART = antiretroviral therapy. CI = confidence interval. IRR = incidence rate ratio. NA = not analysed. NS = not significant on univariate analysis.